Additional Milestone payments.

No definition available.

Name:	tsha_AdditionalMilestonePayments
Namespace Prefix:	tsha_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

License and inventory purchase agreement regulatory related milestones payment.

+ References

No definition available.

+ Details

Name:	tsha_LicenseAndInventoryPurchaseAgreementRegulatoryRelatedMilestonesPayment
Namespace Prefix:	tsha_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

License and inventory purchase agreement sales related milestones payment.

+ References

No definition available.

+ Details

Name:	tsha_LicenseAndInventoryPurchaseAgreementSalesRelatedMilestonesPayment
Namespace Prefix:	tsha_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Minimum licensed product to develop obtain regulatory approval for and commercialize.

+ References

No definition available.

+ Details

Name:	tsha_MinimumLicensedProductToDevelopObtainRegulatoryApprovalForAndCommercialize
Namespace Prefix:	tsha_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Payment of license fee.

+ References

No definition available.

+ Details

Name:	tsha_PaymentOfLicenseFee
Namespace Prefix:	tsha_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Payment of one-time upfront license fee.

+ References

No definition available.

+ Details

Name:	tsha_PaymentOfOneTimeUpfrontLicenseFee
Namespace Prefix:	tsha_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Percentage of fully diluted common stock shares outstanding.

+ References

No definition available.

+ Details

Name:	tsha_PercentageOfFullyDilutedCommonStockSharesOutstanding
Namespace Prefix:	tsha_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Preclinical activities period under sponsored research agreements.

+ References

No definition available.

+ Details

Name:	tsha_PreclinicalActivitiesPeriodUnderSponsoredResearchAgreements
Namespace Prefix:	tsha_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Purchase of clinical materials and reimbursement incurred development costs.

+ References

No definition available.

+ Details

Name:	tsha_PurchaseOfClinicalMaterialsAndReimbursementIncurredDevelopmentCosts
Namespace Prefix:	tsha_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Regulatory related milestones obligation payable.

+ References

No definition available.

+ Details

Name:	tsha_RegulatoryRelatedMilestonesObligationPayable
Namespace Prefix:	tsha_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Sale-related milestones per licensed product and royalties on net sales of licensed products payable.

+ References

No definition available.

+ Details

Name:	tsha_SaleRelatedMilestonesPerLicensedProductAndRoyaltiesOnNetSalesOfLicensedProductsPayable
Namespace Prefix:	tsha_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:	us-gaap_CommonStockSharesIssued
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 985
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481283/985-20-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482916/730-10-50-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 912
-SubTopic 730
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479532/912-730-25-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	srt_CounterpartyNameAxis=tsha_UTSouthwesternAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=tsha_AbeonaCLN1AgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=tsha_AbeonaTherapeuticsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=tsha_AbeonaRettAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Research, Collaboration and License Agreements - Additional Information (Details)	1 Months Ended			3 Months Ended		6 Months Ended		12 Months Ended
	Oct. 31, 2020 USD ($)	Aug. 31, 2020 USD ($)	Apr. 30, 2020 Product	Jun. 30, 2025 USD ($) shares	Jun. 30, 2024 USD ($)	Jun. 30, 2025 USD ($) shares	Jun. 30, 2024 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2024 shares	Oct. 29, 2020 USD ($)	Nov. 30, 2019 shares
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Common stock, shares issued \| shares				272,730,060		272,730,060					204,943,306
Research and development				$ 20,141,000	$ 15,073,000	$ 35,706,000	$ 35,730,000
UT Southwestern Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Preclinical activities period under sponsored research agreements			2 years
Minimum licensed product to develop obtain regulatory approval for and commercialize \| Product			1
Common stock, shares issued \| shares													2,179,000
Percentage of fully diluted common stock shares outstanding													20.00%
Abeona CLN1 Agreements
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Additional milestone payments						0
License fee payment		$ 3,000,000
Purchase of clinical materials and reimbursement incurred development costs	$ 4,000,000
Research and development									$ 3,000,000	$ 7,000,000
Abeona CLN1 Agreements \| Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
License and inventory purchase agreement regulatory related milestones payment		26,000,000
License and inventory purchase agreement sales related milestones payment		$ 30,000,000
Abeona \| Abeona Rett Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Additional milestone payments						0
Research and development						$ 1,000,000.0		$ 3,500,000
Payment of one-time upfront license fee										$ 3,000,000
Abeona \| Maximum \| Abeona Rett Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Regulatory related milestones obligation payable												$ 26,500,000
Sale-related milestones per licensed product and royalties on net sales of licensed products payable												$ 30,000,000